Glioblastoma (GBM) is the most common and aggressive intraparenchymal primary brain tumor in adults. The principal reasons for the poor outcomes of GBM are the high rates of recurrence and resistance to chemotherapy. The aim of this study was to determine the role of tailored cellular therapy for GBM with a poor prognosis and compare the activity of dendritic cells (DCs) that have encountered GBM cells. Detecting the correlations between methylation and expression of MGMT and PTEN genes and GBM cancer stem cells (CSCs) markers after co-cultures with a mononuclear cell cocktail are also aims for this study. Allogenic umbilical cord blood (UCB)-derived DCs were labeled with the CD11a and CD123 for immature DCs, and CD80 and CD11c for mature DCs. CD34, CD45, and CD56 cells were isolated from allogenic UCB for using in DCs maturation. GBM CSCs were detected with CD133/1 and CD111 antibodies after co-culture studies. DC activation was carried out via GBM cells including CD133 and CD111 cells and a mononuclear cells cocktail including CD34, CD45, and CD56 natural killer cells. Real-time PCR was performed to detect the expression and promoter methylation status of PTEN and MGMT genes. The expression of CSCs markers was found in all GBM cases, and a statistically significant correlation was found among them after co-culture studies. The most pronounced affinity of DCs to GBM cells was observed at dilutions between 1/4 and 1/256 in co-cultures. There was a statistically significant correlation between cellularity and granularity ratios for CD123 and CD11c. PTEN and MGMT gene expression and methylation values were evaluated with respect to CSCs expression and no statistical significance was found. Activation of DCs might associate with CSCs and the mononuclear cells cocktail including CD34, CD45, and CD56 cells which were obtained from allogenic UCB.
Glioblastoma Cancer stem-like cells Dendritic cells PTEN MGMT
This is a preview of subscription content, log in to check access.
This study was supported by ONKIM Stem Cell Technologies. We acknowledge Pınar Hüner and Cem Kulen from ONKIM Stem Cell Technologies for their contributions in the study.
Conflict of interest
We confirm that this manuscript has not been published elsewhere and is not under consideration by another journal. We do not have any conflict of interest.
Rock K, et al. A clinical review of treatment outcomes in glioblastoma multiforme—the validation in a non-trial population of the results of a randomised Phase III clinical trial: has a more radical approach improved survival? Br J Radiol. 1017;85:e729–33.CrossRefGoogle Scholar
Stupp R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.PubMedCrossRefGoogle Scholar
Stupp R, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–66.PubMedCrossRefGoogle Scholar
Han SJ, et al. Biologic principles of immunotherapy for malignant gliomas. Neurosurg Clin North Am. 2010;21(1):1–16.CrossRefGoogle Scholar
Choucair AK, et al. Development of multiple lesions during radiation therapy and chemotherapy in patients with gliomas. J Neurosurg. 1986;65(5):654–8.PubMedCrossRefGoogle Scholar
Green SB, et al. Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep. 1983;67(2):121–32.PubMedGoogle Scholar
Deutsch M, et al. Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. Int J Radiat Oncol Biol Phys. 1989;16(6):1389–96.PubMedCrossRefGoogle Scholar
Chen R, et al. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell. 2010;17(4):362–75.PubMedCrossRefGoogle Scholar
Joo KM, et al. Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab Invest. 2008;88(8):808–15.PubMedCrossRefGoogle Scholar
Pellegatta S, et al. Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. Cancer Res. 2006;66(21):10247–52.PubMedCrossRefGoogle Scholar
Paola B, et al. CD133 is essential for glioblastoma stem cell maintenance. Stem Cells. 2013;31:857–69.CrossRefGoogle Scholar
Liu G, et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer. 2006;5:67.PubMedCrossRefGoogle Scholar
Pallini R, et al. Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res. 2008;14(24):8205–12.PubMedCrossRefGoogle Scholar
Qiang L, et al. Isolation and characterization of cancer stem like cells in human glioblastoma cell lines. Cancer Lett. 2009;279(1):13–21.PubMedCrossRefGoogle Scholar
Salmaggi A, et al. Glioblastoma-derived tumorospheres identify a population of tumor stem-like cells with angiogenic potential and enhanced multidrug resistance phenotype. Glia. 2006;54(8):850–60.PubMedCrossRefGoogle Scholar
Beier D, et al. CD133(+) and CD133(−) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 2007;67(9):4010–5.PubMedCrossRefGoogle Scholar
Kang MK, Kang SK. Tumorigenesis of chemotherapeutic drug-resistant cancer stem-like cells in brain glioma. Stem Cells Dev. 2007;16(5):837–47.PubMedCrossRefGoogle Scholar
Friedman GK, et al. Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111. J Neurooncol. 2009;95(2):199–209.PubMedCrossRefGoogle Scholar
Harada Y, et al. Cytokine-based log-scale expansion of functional murine dendritic cells. PLoS ONE. 2009;4(8):e6674.PubMedCrossRefGoogle Scholar
Harada Y, et al. Cytokine-based high log-scale expansion of functional human dendritic cells from cord-blood CD34-positive cells. Sci Rep. 2011;1:174.PubMedCrossRefGoogle Scholar
Wehner R, et al. The bidirectional crosstalk between human dendritic cells and natural killer cells. J Innate Immun. 2011;3(3):258–63.PubMedCrossRefGoogle Scholar
Martin-Fontecha A, et al. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol. 2004;5(12):1260–5.PubMedCrossRefGoogle Scholar
Morandi B, et al. NK cells of human secondary lymphoid tissues enhance T cell polarization via IFN-gamma secretion. Eur J Immunol. 2006;36(9):2394–400.PubMedCrossRefGoogle Scholar
Mocikat R, et al. Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity. 2003;19(4):561–9.PubMedCrossRefGoogle Scholar
Altin JG, Sloan EK. The role of CD45 and CD45-associated molecules in T cell activation. Immunol Cell Biol. 1997;75(5):430–45.PubMedCrossRefGoogle Scholar
Piccioli D, et al. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med. 2002;195(3):335–41.PubMedCrossRefGoogle Scholar